Published in Cancer Weekly, February 15th, 2005
The clinical study will evaluate the safety profile and preliminary incidence and duration of clinical benefits of novel escalating-dose and administration schedules of docetaxel in combination with multiple doses of QUADRAMET.
"We are appreciative of the support and interest generated by both medical researchers and pharmaceutical companies as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.